An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it was safe and produced images with the same pattern as generator produced Pertechnetate. This study is now being done in larger numbers of patients to again show that the imaging pattern of both agents is the same, and to again demonstrate its safety.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AHS Cancer Control Alberta
• Collaborator: Cross Cancer Institute
• Treatments: Sodium Pertechnetate Tc 99m

Criteria

Inclusion Criteria:

• thyroid cancer, or

• Head and Neck cancer for salivary gland transfer

• age 18-79

• biochemical parameters < 5x ULN

• WBC > 3.0/uL

• ANC > 1.5/uL

• platelets > 75,000/uL

• hemoglobin > 10 g/dL

• Karnofsky 50-100

Exclusion Criteria:

• nursing or pregnant females

• < 18 or > 79 Years

• uncontrolled asthma

• acute iritis

• narrow angle glaucoma

• previous radiation to head/neck